Literature DB >> 31650484

On Research Progress of Western and Chinese Medicine Treatment on Pre-Rheumatoid Arthritis.

Xiang-Yu Kong1, Cheng-Ping Wen2.   

Abstract

Pre-rheumatoid arthritis is the inevitable phase before the actual onset of rheumatoid arthritis and has the crucial clinical significance of early controlling and preventing disease progression. Full understanding, from both Western medicine (WM) and Chinese medicine (CM), could offer new ideas for decision making in clinical and mechanism research. This paper reviews the novel studies of WM and CM to discuss the advantages and potential mechanisms working behind.

Entities:  

Keywords:  Chinese medicine; Western medicine; pre-rheumatoid arthritis

Mesh：

Year:  2019        PMID： 31650484     DOI： 10.1007/s11655-019-3223-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


  27 in total

1.  The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.

Authors:  Klaus P Machold; Robert Landewé; Josef S Smolen; Tanja A Stamm; Désirée M van der Heijde; Kirsten N Verpoort; Kerstin Brickmann; Janitzia Vázquez-Mellado; Dimitri E Karateev; Ferdinand C Breedveld; Paul Emery; Thomas W J Huizinga
Journal:  Ann Rheum Dis       Date:  2010-03       Impact factor: 19.103

Review 2.  Efficacy and Safety of GuiZhi-ShaoYao-ZhiMu Decoction for Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  James W Daily; Ting Zhang; Shihua Cao; Sunmin Park
Journal:  J Altern Complement Med       Date:  2017-06-13       Impact factor: 2.579

3.  Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study.

Authors:  Eriko Kudo-Tanaka; Takashi Shimizu; Takuro Nii; Satoru Teshigawara; Maiko Yoshimura; Akane Watanabe; Soichiro Tsuji; Hideki Tsuboi; Makoto Hirao; Akiko Yura; Yoshinori Harada; Makoto Sueishi; Yasuo Suenaga; Noriyuki Chiba; Takeharu Tonai; Koichiro Saisho; Atsushi Ogata; Masato Matsushita; Jun Hashimoto; Shiro Ohshima; Shigeto Tohma; Yukihiko Saeki
Journal:  Mod Rheumatol       Date:  2015-04-30       Impact factor: 3.023

4.  Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).

Authors:  Jill van Aken; Lotte Heimans; Henrike Gillet-van Dongen; Karen Visser; H Karel Ronday; Irene Speyer; André J Peeters; Tom W J Huizinga; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2013-01-19       Impact factor: 19.103

Review 5.  Effects and safety of Sinomenine in treatment of rheumatoid arthritis contrast to methotrexate: a systematic review and Meta-analysis.

Authors:  Weiwei Liu; Xian Qian; Wei Ji; Yan Lu; Gang Wei; Yue Wang
Journal:  J Tradit Chin Med       Date:  2016-10       Impact factor: 0.848

6.  Prevotella copri in individuals at risk for rheumatoid arthritis.

Authors:  Axel Finckh; Till Strowig; Deshire Alpizar-Rodriguez; Till Robin Lesker; Achim Gronow; Benoît Gilbert; Elena Raemy; Celine Lamacchia; Cem Gabay
Journal:  Ann Rheum Dis       Date:  2019-02-13       Impact factor: 19.103

7.  EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.

Authors:  Danielle M Gerlag; Karim Raza; Lisa G M van Baarsen; Elisabeth Brouwer; Christopher D Buckley; Gerd R Burmester; Cem Gabay; Anca I Catrina; Andrew P Cope; François Cornelis; Solbritt Rantapää Dahlqvist; Paul Emery; Stephen Eyre; Axel Finckh; Steffen Gay; Johanna M Hazes; Annette van der Helm-van Mil; Tom W J Huizinga; Lars Klareskog; Tore K Kvien; Cathryn Lewis; Klaus P Machold; Johan Rönnelid; Dirkjan van Schaardenburg; Georg Schett; Josef S Smolen; Sue Thomas; Jane Worthington; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2012-03-02       Impact factor: 19.103

8.  A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Authors:  Michael E Weinblatt; Iain B McInnes; Joel M Kremer; Pedro Miranda; Jiri Vencovsky; Xiang Guo; Wendy I White; Patricia C Ryan; Alex Godwood; Marius Albulescu; David Close; Gerd R Burmester
Journal:  Arthritis Rheumatol       Date:  2018-01       Impact factor: 10.995

9.  Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.

Authors:  Danielle M Gerlag; Mary Safy; Karen I Maijer; Man Wai Tang; Sander W Tas; Mirian J F Starmans-Kool; Astrid van Tubergen; Matthijs Janssen; Maria de Hair; Monika Hansson; Niek de Vries; Aeilko H Zwinderman; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2018-12-01       Impact factor: 19.103

10.  Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study.

Authors:  C Rakieh; J L Nam; L Hunt; E M A Hensor; S Das; L-A Bissell; E Villeneuve; D McGonagle; R Hodgson; A Grainger; R J Wakefield; P G Conaghan; P Emery
Journal:  Ann Rheum Dis       Date:  2014-04-12       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.